Corporate News 10-Nov-23
Biocon Biologics divests its non-crore branded formulations biz in India
Biocon Biologics, a subsidiary of Biocon has divested the businesses in relation to its non-core branded formulations in India, comprising, inter alia, of generic dermatology and nephrology small molecule formulations (BFI Non-Core Business) to Eris Lifesciences on a ‘slump sale' basis.
Previous News
Biocon’s board OKs to raise Rs 4,500-cr
( Hot Pursuit - 24-Apr-25 08:11 )
Board of Biocon approves fund raising up to Rs 4,500 cr
( Corporate News - 23-Apr-25 20:05 )
Biocon to consider fund Raising
( Corporate News - 21-Apr-25 09:37 )
Biocon surges on U.S. deal for Eylea copycat drug
( Hot Pursuit - 15-Apr-25 09:58 )
Biocon Biologics inks a settlement and license agreement with Regeneron
( Corporate News - 15-Apr-25 09:29 )
Biocon Biologics receives USFDA approval for Jobevne™ (Biosimilar Bevacizumab)
( Corporate News - 10-Apr-25 13:25 )
Biocon unit gets U.S. FDA nod for cancer drug biosimilar
( Hot Pursuit - 10-Apr-25 11:07 )
Board of Biocon approves CP issuance of Rs 600 cr
( Corporate News - 05-Apr-25 14:34 )
Biocon to table results
( Corporate News - 03-Apr-25 09:49 )
Biocon to convene board meeting
( Corporate News - 02-Apr-25 10:19 )
Biocon’s board to mull fund raising plans on 4 April
( Hot Pursuit - 02-Apr-25 08:09 )
Other Stories
Muthoot Finance announces board meeting date
26-Apr-25 17:29
Triveni Glass to conduct board meeting
26-Apr-25 17:29
Wisec Global to conduct board meeting
26-Apr-25 17:29
Transwarranty Finance announces board meeting date
26-Apr-25 17:29
Board of Associated Alcohols & Breweries recommends Final Dividend
26-Apr-25 17:02
Tahmar Enterprises announces board meeting date
26-Apr-25 16:59
Adani Ports & Special Economic Zone to convene board meeting
26-Apr-25 16:59
Rajdarshan Industries to discuss results
26-Apr-25 16:59
Goodluck India to conduct board meeting
26-Apr-25 16:59
Navkar Corporation to conduct AGM
26-Apr-25 16:56
Back
Top